| Autor: |
Sanchez-Mas J; Instituto Murciano de Investigación Biomédica (IMIB), Facultad de Medicina, University of Murcia, Murcia, Spain.; Departamento de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Moncada, Spain., Lax A; Instituto Murciano de Investigación Biomédica (IMIB), Facultad de Medicina, University of Murcia, Murcia, Spain., Asensio-Lopez MC; Instituto Murciano de Investigación Biomédica (IMIB), Facultad de Medicina, University of Murcia, Murcia, Spain., Lencina M; Pathological Anatomy Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain., Fernandez-Del Palacio MJ; Veterinary Teaching Hospital, Veterinary Medicine and Surgery Department, University of Murcia, Murcia, Spain., Soriano-Filiu A; Instituto Murciano de Investigación Biomédica (IMIB), Facultad de Medicina, University of Murcia, Murcia, Spain., de Boer RA; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Pascual-Figal DA; Instituto Murciano de Investigación Biomédica (IMIB), Facultad de Medicina, University of Murcia, Murcia, Spain. dpascual@um.es.; Cardiology Department, Hospital Universitario Virgen de la Arrixaca, LAIB, Room 2.52, Av. Buenavista s/n, 30120, Murcia, Spain. dpascual@um.es.; CIBER in Cardiovascular Diseases (CIBERCV), Madrid, Spain. dpascual@um.es. |
| Abstrakt: |
Sprague Dawley rats were subjected to acute myocardial infarction (AMI) by permanent ligation of the left anterior descending coronary artery. At the time of AMI, a subcutaneous mini-osmotic pump was implanted and animals were randomized into three groups, according to the intravenous therapy received during the first 72 h: placebo-treated (saline), serelaxin10-treated (SRLX10 = 10 μg/kg/day), or serelaxin30-treated (SRLX30 = 30 μg/kg/day). Treatment with SRLX30 reduced the expression of inflammatory cytokines and chemokines, as well as the infiltration of macrophages, and increased the expression of pro-angiogenic markers and vessel density in the infarcted myocardium after 7 days. SRLX30 did not reduce early myocardial fibrosis but reduced myocardial levels of sST2 and galectin-3. No significant effects were observed with SRLX10 treatment. A significant correlation was observed between plasma levels of serelaxin and effect measures. The results suggest serelaxin has a protective effect in early processes of cardiac remodeling after AMI. |
Full text from SpringerLink